Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2022-08, Vol.22 (8), p.566-568
Main Authors: Hughes, David M., Henshaw, Lynnette, Blevins, Frances, Edwards, Camille, Lerner, Adam, Sloan, John Mark, Sanchorawala, Vaishali
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2022.03.003